RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

New article explores how specific types of interferons control RNA virus infection

Respiratory and intestinal infections caused by RNA viruses stimulate infected cells to produce interferons, which can act alone or in combination to block virus replication.

27 Jun 2014

USAMRIID scientists propose new standards to sequence viral genomes

Scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) have proposed a set of standards aimed at developing a common "language" among investigators working to sequence viral genomes and characterize viral stocks.

26 Jun 2014

Gene partnership may be fueling cancer spread in as much as 20% of cancers

A key cancer-causing gene, responsible for up to 20 percent of cancers, may have a weak spot in its armor, according to new research from the Masonic Cancer Center, University of Minnesota.

25 Jun 2014

Discovery provides scientists with better understanding of limiting uncontrolled cell growth

Biologists at UC San Diego have found the "missing link" in the chemical system that enables animal cells to produce ribosomes-the thousands of protein "factories" contained within each cell that manufacture all of the proteins needed to build tissue and sustain life.

24 Jun 2014

Investigators discover novel cellular genes by uncovering uncharacterized RNAs that encode proteins

Case Western Reserve School of Medicine scientists have made an extraordinary double discovery. First, they have identified thousands of novel long non-coding ribonucleic acid (lncRNA) transcripts.

23 Jun 2014

Celsion acquires all assets of EGEN

Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.

21 Jun 2014

Yap1 oncogene drives recurrence and progression of pancreatic cancer

Pancreatic cancer tumors addicted to mutant Kras signaling for their growth and progression have a ready-made substitute to tap if they're ever forced to go cold-turkey on the mutant oncogene, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cell.

20 Jun 2014

Weizmann Institute scientists 'fingerprint' a culprit in depression and anxiety disorders

According the World Health Organization, such mood disorders as depression affect some 10% of the world's population and are associated with a heavy burden of disease. That is why numerous scientists around the world have invested a great deal of effort in understanding these diseases. Yet the molecular and cellular mechanisms that underlie these problems are still only partly understood.

20 Jun 2014

Research provides unique insight into lncRNAs that regulate lung development

It's a long way from DNA to RNA to protein, and only about two percent of a person's genome is eventually converted into proteins.

19 Jun 2014

NuGEN 2014 Genomics Grant Challenge announced

NuGEN Technologies, Inc., a market leader in the development of innovative sample preparation solutions for Next Generation Sequencing (NGS) applications, has announced the NuGEN 2014 Genomics Grant Challenge.

18 Jun 2014

Researchers identify muscle-building mechanism that could be important in addressing sarcopenia

Sarcopenia - the significant loss of muscle mass and function that can occur as we age - is associated with many chronic conditions such as diabetes, high cholesterol and obesity.

18 Jun 2014

Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute

Trovagene, Inc. today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.

16 Jun 2014

Arrowhead Research joins with broad-market Russell 3000 Index

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.

16 Jun 2014

Healthcare Corporate Access Day to be held on June 24, 2014

ROTH Capital Partners, a full-service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Healthcare Corporate Access Day on Tuesday, June 24, 2014, at the Dorchester Hotel in London, U.K.

11 Jun 2014

Research to identify new potential targets for cancer therapy

In 2012, about 8.2 million people died of cancer making the disease a major cause of death worldwide. According to the WHO World Cancer Report 2014, this figure is expected to rise within the next two decades.

11 Jun 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Research on viral RNA may help scientists develop treatments against infectious diseases

In an article published in the scientific journal Nature, a University of Colorado School of Medicine researcher and colleagues explain how RNA molecules found in certain viruses mimic the shape of other molecules as part of a strategy to 'hijack' the cell and make more viruses.

10 Jun 2014

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-DMPKRx. Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement.

9 Jun 2014

Certain molecules in seminal fluid indicate presence and severity of prostate cancer

Improved diagnosis and management of one of the most common cancers in men - prostate cancer - could result from research at the research at the University of Adelaide, which has discovered that seminal fluid (semen) contains biomarkers for the disease.

9 Jun 2014

RNA News and Research

Further Reading

New article explores how specific types of interferons control RNA virus infection

USAMRIID scientists propose new standards to sequence viral genomes

Gene partnership may be fueling cancer spread in as much as 20% of cancers

Discovery provides scientists with better understanding of limiting uncontrolled cell growth

Investigators discover novel cellular genes by uncovering uncharacterized RNAs that encode proteins

Celsion acquires all assets of EGEN

Yap1 oncogene drives recurrence and progression of pancreatic cancer

Weizmann Institute scientists 'fingerprint' a culprit in depression and anxiety disorders

Research provides unique insight into lncRNAs that regulate lung development

NuGEN 2014 Genomics Grant Challenge announced

Researchers identify muscle-building mechanism that could be important in addressing sarcopenia

Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute

Arrowhead Research joins with broad-market Russell 3000 Index

Healthcare Corporate Access Day to be held on June 24, 2014

Research to identify new potential targets for cancer therapy

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Celsion signs definitive asset purchase agreement to acquire EGEN

Research on viral RNA may help scientists develop treatments against infectious diseases

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Certain molecules in seminal fluid indicate presence and severity of prostate cancer

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo